These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28927711)

  • 1. Efficacy, tolerability, and retention rates of zonisamide in older adult patients with focal-onset epilepsy: Experiences from two tertiary epilepsy centers.
    Doğan EA; Genç E; Genç BO; Erdoğan Ç
    Epilepsy Behav; 2017 Nov; 76():19-23. PubMed ID: 28927711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term efficacy and safety of zonisamide as adjunctive treatment for refractory partial seizures: a multicenter open-label single-arm trial in Korean patients.
    Heo K; Lee BI; Yi SD; Cho YW; Shin DJ; Song HK; Kim OJ; Park SP; Kim SE; Kim SH; Lee JH; Kim KS; Lee SJ
    Seizure; 2012 Apr; 21(3):188-93. PubMed ID: 22226572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [ZONISAMIDE: FIRST CHOICE AMONG THE FIRST-LINE ANTIEPILEPTIC DRUGS IN FOCAL EPILEPSY].
    Janszky J; Horvath R; Komoly S
    Ideggyogy Sz; 2015 May; 68(5-6):149-53. PubMed ID: 26182605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy.
    Kothare SV; Valencia I; Khurana DS; Hardison H; Melvin JJ; Legido A
    Epileptic Disord; 2004 Dec; 6(4):267-70. PubMed ID: 15634623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Zonisamide as add-on treatment for focal epilepsies. An outcome analysis of 74 patients].
    Wellmer S; Wellmer J; Bauer J
    Nervenarzt; 2008 Dec; 79(12):1416, 1418-23. PubMed ID: 18633587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retention, dosing, tolerability and patient reported seizure outcome of Zonisamide as only add-on treatment under real-life conditions in adult patients with partial onset seizures: Results of the observational study ZOOM.
    Hamer H; Baulac M; McMurray R; Kockelmann E
    Seizure; 2016 Jan; 34():66-73. PubMed ID: 26735004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy.
    Shinnar S; Pellock JM; Conry JA
    Eur J Paediatr Neurol; 2009 Jan; 13(1):3-9. PubMed ID: 18343174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and long-term efficacy of zonisamide as adjunctive therapy for focal epilepsy.
    Schulze-Bonhage A
    Expert Rev Neurother; 2015; 15(8):857-65. PubMed ID: 26144543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: results of a phase III, randomized, double-blind study.
    Baulac M; Patten A; Giorgi L
    Epilepsia; 2014 Oct; 55(10):1534-43. PubMed ID: 25109239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures.
    Brodie MJ; Duncan R; Vespignani H; Solyom A; Bitenskyy V; Lucas C
    Epilepsia; 2005 Jan; 46(1):31-41. PubMed ID: 15660766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.
    Baulac M; Brodie MJ; Patten A; Segieth J; Giorgi L
    Lancet Neurol; 2012 Jul; 11(7):579-88. PubMed ID: 22683226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Could Adult European Pharmacoresistant Epilepsy Patients Be Treated With Higher Doses of Zonisamide?
    Miro J; Jaraba S; Juvany R; Santurino M; Cobo S; Falip M
    Clin Neuropharmacol; 2016; 39(3):121-4. PubMed ID: 26818046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy.
    Marinas A; Villanueva V; Giráldez BG; Molins A; Salas-Puig J; Serratosa JM
    Epileptic Disord; 2009 Mar; 11(1):61-6. PubMed ID: 19264587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures.
    Sackellares JC; Ramsay RE; Wilder BJ; Browne TR; Shellenberger MK
    Epilepsia; 2004 Jun; 45(6):610-7. PubMed ID: 15144425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective audits with newer antiepileptic drugs in focal epilepsy: insights into population responses?
    Brodie MJ; Kelly K; Stephen LJ
    Epilepsy Behav; 2014 Feb; 31():73-6. PubMed ID: 24361766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term retention rate of zonisamide in patients with epilepsy: an observational study.
    Kim DW; Choi K; Moon HS; Oh J
    Clin Neuropharmacol; 2014; 37(5):133-5. PubMed ID: 25229169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy.
    Kothare SV; Kaleyias J; Mostofi N; Valencia I; Melvin JJ; Hobdell E; Khurana DS; Legido A
    Pediatr Neurol; 2006 May; 34(5):351-4. PubMed ID: 16647993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy.
    Lee YJ; Kang HC; Seo JH; Lee JS; Kim HD
    Brain Dev; 2010 Mar; 32(3):208-12. PubMed ID: 19304420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective audit of adjunctive zonisamide in an everyday clinical setting.
    Stephen LJ; Kelly K; Wilson EA; Parker P; Brodie MJ
    Epilepsy Behav; 2010 Apr; 17(4):455-60. PubMed ID: 20207201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retention rate of zonisamide in intractable epilepsy.
    Nakken KO; Lindstrøm P; Andersen H
    Acta Neurol Scand; 2015 May; 131(5):268-74. PubMed ID: 25644477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.